Using Intradermal Rabies Vaccine to Boost Immunity
Author Information
Author(s): David Brown, Anthony R. Fooks, Martin Schweiger
Primary Institution: Virus Reference Department, Centre for Infections, HPA, London, UK
Hypothesis
Adequate levels of rabies antibodies can be achieved by administering a cumulative dose of 2.0 IU of rabies vaccine intradermally over at least three occasions.
Conclusion
The study found that all participants demonstrated adequate rabies antibody levels after receiving booster doses of the intradermal rabies vaccine.
Supporting Evidence
- All participants demonstrated post-booster antibody titres higher than the minimum considered consistent with immunity to rabies.
- No adverse effects of intradermal rabies vaccine boosting were noted.
- The mean rise in antibody titre was 17.15 IU/mL.
Takeaway
The study shows that giving a special rabies vaccine in small doses can help people who didn't have enough protection before to build up their immunity.
Methodology
Participants received booster doses of intradermal rabies vaccine and blood samples were taken to measure antibody levels before and after vaccination.
Potential Biases
Blood samples were tested in a blinded manner to reduce bias.
Limitations
The small sample size may not represent the broader population's response to the vaccine.
Participant Demographics
The majority of participants were women aged 20 to 71 years.
Statistical Information
P-Value
<0.01
Confidence Interval
CI 0.12–0.25 for pre-booster; CI 1.48–33.19 for post-booster
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website